Macro Bank Inc. filed a Form 6-K on November 3, 2026, disclosing that Banco Macro S.A. acquired 45,298 of its own common shares under Argentine regulatory provisions, with the submission translated from a notice sent to Argentina's Comisión Nacional de Valores on the same …
The Procter & Gamble Company filed a Form 8-K on November 3, 2026, disclosing the closing of an underwritten public offering of four tranches of euro-denominated notes totaling EUR 3,250,000,000 in aggregate principal amount.
The Procter & Gamble Company filed a Form 8-A on November 3, 2026, to register four series of debt securities on the New York Stock Exchange under Section 12(b) of the Securities Exchange Act of 1934.
John M. Leonard, President and CEO of Intellia Therapeutics, Inc. (NASDAQ:NTLA), filed a Form 4 on November 3, 2026, disclosing the sale of 9,000 shares of common stock on November 2, 2026, under a pre-established Rule 10b5-1 trading plan.
Jeffrey D. Fick, Chief Legal Officer of RLI Corp, filed a Form 4 on November 3, 2026, disclosing the acquisition of 7,500 stock options in RLI Corp common stock on November 2, 2026.
Karen A. Swager, Executive Vice President of Operations at The Mosaic Company (NYSE:MOS), filed a Form 4 on November 3, 2026, disclosing transactions dated November 2, 2026, involving the vesting of restricted stock units and a tax-withholding share disposition.
National Bank Holdings Corporation filed a Form 8-K on November 3, 2026, disclosing that its Board of Directors declared a quarterly cash dividend of $0.33 per share of Class A common stock, payable December 15, 2026.
Robert Nielsen III, Senior Vice President of Operations at Waste Connections, Inc., filed a Form 4 on November 3, 2026, disclosing three sales of common shares between October 30 and November 2, 2026.
Greg W. McIntosh, EVP and Chief Commercial Officer of Iron Mountain Inc, filed a Form 4 on November 3, 2026, disclosing the sale of 5,000 shares of common stock on November 2, 2026, under a pre-established Rule 10b5-1 trading plan.
Shawn Cross, Chief Financial Officer of Pacira BioSciences, Inc. (NASDAQ:PCRX), filed a Form 4 on November 3, 2026, disclosing a share withholding transaction on October 30, 2026, related to the vesting of a restricted stock unit award.